Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacin for the Treatment of MASLD
NCT06843148Recruiting
- Sponsor
- Université de Sherbrooke
- Start
- Jun 2026
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Placebo group with Niacin group (2 arms). Primary endpoint: Niacin-induced reduction in hepatic total fatty acids flux at 28 weeks. Started Jun 2026; status: recruiting.
02
Drugs
niacin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT06843148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843148.